Lebrikizumab improves anxiety and depression symptoms in adolescents with moderate-to-severe atopic dermatitis, with significant PROMIS score improvements after 52 weeks. The therapy enhances disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback